rmdopen.bmj11h
Targeting the IL-17A pathway for therapy in early-stage tendinopathy
Objectives Tendinopathy is a frequent clinical problem and represents an extraordinary health economic and socioeconomic burden with high unmet medical needs. Recent clinical evidence suggests ...
rmdopen.bmj4d
From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?
It is believed that therapy for rheumatoid arthritis (RA) is the most effective and beneficial within a short time frame around RA diagnosis. This insight has caused a shift from research in patients ...
rmdopen.bmj11d
Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial
Objectives Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab ...
rmdopen.bmj14d
Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study
Objective Evaluate the performance of FRAX®, with and without bone mineral densitometry (BMD), in predicting the occurrence of fragility fractures over 10 years. Methods Participants aged ≥40 years at ...
rmdopen.bmj15d
Influence of sacroiliac joint variation on clinical features of axial spondyloarthritis: a comparative analysis
Objectives Anatomical variation of the sacroiliac (SI) joints is common and specific variants are associated with erosions and bone marrow oedema on imaging. Our investigation aims to evaluate whether ...
rmdopen.bmj15d
Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies
2 Centre de Référence des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France Objective To describe systemic sclerosis (SSc) with myopathy in patients without classic ...
rmdopen.bmj17d
Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis
1 Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, Netherlands 2 Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands Objectives Methotrexate ...
rmdopen.bmj19d
Polymyalgia rheumatica: an autoinflammatory disorder?
Polymyalgia rheumatica (PMR) is an elderly onset syndrome characterised by aching and stiffness in the shoulders and the pelvic girdle associated to increased levels of acute phase reactants and rapid ...
rmdopen.bmj21d
CAR T cells for treating autoimmune diseases
Autoimmune disorders occur when immune cells go wrong and attack the body’s own tissues. Currently, autoimmune disorders are largely treated by broad immunosuppressive agents and blocking antibodies, ...
rmdopen.bmj25d
Anifrolumab: the new frontier in the treatment of genetic interferonopathies
Understanding the precise mechanisms of monogenic autoinflammatory diseases provides crucial insights into the complex pathophysiology of more common multifactorial diseases, while treatments ...
rmdopen.bmj28d
Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
1 Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital, Le Kremlin-Bicêtre, France 2 INSERM U1184, Center for Immunology of Viral Infections and Autoimmune ...
rmdopen.bmj28d
Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy
Objectives To evaluate the sensitivity to change of ultrasound structural gout lesions, as defined by the Outcome Measures in Rheumatology (OMERACT) ultrasound group, in patients with gout during ...